Xponance Inc. Raises Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Xponance Inc. boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,240 shares of the company’s stock after buying an additional 315 shares during the quarter. Xponance Inc.’s holdings in Henry Schein were worth $1,331,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Natixis Advisors LLC increased its position in shares of Henry Schein by 18.8% during the third quarter. Natixis Advisors LLC now owns 81,877 shares of the company’s stock valued at $5,969,000 after acquiring an additional 12,930 shares during the last quarter. Thrivent Financial for Lutherans increased its position in shares of Henry Schein by 1,848.9% during the third quarter. Thrivent Financial for Lutherans now owns 105,415 shares of the company’s stock valued at $7,685,000 after acquiring an additional 100,006 shares during the last quarter. Pathstone Holdings LLC increased its position in shares of Henry Schein by 3.1% during the third quarter. Pathstone Holdings LLC now owns 24,028 shares of the company’s stock valued at $1,752,000 after acquiring an additional 732 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Henry Schein in the third quarter valued at approximately $515,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Henry Schein by 2.8% in the third quarter. PNC Financial Services Group Inc. now owns 86,143 shares of the company’s stock valued at $6,280,000 after purchasing an additional 2,380 shares in the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Henry Schein

In related news, CEO Bradford C. Connett sold 4,036 shares of the company’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the company’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. UBS Group dropped their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, February 26th. Jefferies Financial Group lifted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Wells Fargo & Company assumed coverage on shares of Henry Schein in a report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price objective for the company. Mizuho assumed coverage on shares of Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price objective for the company. Finally, Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $69.00 to $84.00 in a report on Monday, January 6th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.10.

Henry Schein Stock Down 1.5 %

Shares of NASDAQ:HSIC opened at $69.39 on Friday. The company has a market capitalization of $8.62 billion, a PE ratio of 28.56, a P/E/G ratio of 2.13 and a beta of 0.90. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.49. The firm has a 50 day simple moving average of $74.82 and a 200-day simple moving average of $72.61.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.66 EPS. On average, equities analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.